Company Filing History:
Years Active: 2021
Title: The Innovations of Stéphane Guerif: Pioneering Antibody Research
Introduction
Stéphane Guerif is an innovative inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-based therapies. With a focus on combating cancer, his research and inventions have the potential to revolutionize treatment options.
Latest Patents
Stéphane holds a notable patent that focuses on anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123. The invention elaborates on antibody-like binding proteins that uniquely interact with both CD3 and additional antigens, specifically CD123. This patent also encompasses pharmaceutical compositions containing these antibodies, enhancing their therapeutic application for cancer treatment. Additionally, it relates to isolated nucleic acids, vectors, and host cells encoding the antibody-like binding proteins, highlighting their importance in both diagnostic and therapeutic settings.
Career Highlights
Stéphane Guerif is an integral member of Sanofi, a leading biopharmaceutical company. His role at Sanofi places him at the forefront of innovative research and development aimed at creating effective cancer therapies. He has contributed to the advancement of new treatment methodologies, advocating for the vital role antibodies play in modern medicine.
Collaborations
Throughout his career, Stéphane has collaborated with other prominent scientists and researchers, including Jana Albrecht and Cédric Barriere. These collaborations foster a dynamic environment for innovative thinking and problem-solving, ultimately driving progress in cancer treatment research.
Conclusion
Stéphane Guerif's work exemplifies the significant strides being made in antibody engineering and cancer treatment. His patent on anti-CD3 and anti-CD123 antibodies not only showcases his inventive capabilities but also underscores the collaborative efforts that are essential in the scientific community. As he continues to work at Sanofi, the impact of his contributions will likely influence future advancements in biotechnology and patient care.